Gene therapy for head and neck cancer

Advances in Oto-Rhino-Laryngology

Volumn 70, Issue , 2011, Pages 141-151

  Abuzeid, Waleed M ^a,c   Li, Daqing ^b   O'Malley Jr , Bert W ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HUMAN; METHODOLOGY; MORTALITY;

GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 79952430050     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000322490     Document Type: Article

References (66)

1. Aiuti A, et al: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413. (Pubitemid 34734219)
2. Chisholm E, et al: Gene therapy in head and neck cancer: a review. Postgrad Med J 2007;83:731-737.
3. Harrington KJ, Nutting CM, Pandha HS: Gene therapy for head and neck cancer. Cancer Metastasis Rev 2005;24:147-164. (Pubitemid 40576069)
4. National Cancer Institute Surveillance Epidemiology and End Results. 1973-2006.
5. Capecchi MR: High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980;22:479-488. (Pubitemid 11199905)
6. Heinzerling L, et al: Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005;16:35-48. (Pubitemid 40250330)
7. Walther W, et al: Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 2008; 14:7545-7553.
8. Yang NS, et al: In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87:9568-9572.
9. Daud AI, et al: Phase I trial of interleukin- 12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008;26:5896-5903.
10. OMalley BW Jr, et al: Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 2005;115:391-404.
11. Yoo GH, et al: Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001;7:1237-1245. (Pubitemid 32708675)
12. Villaret D, et al: A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002;24:661-669. (Pubitemid 34734362)
13. Sikes ML, et al: In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum Gene Ther 1994; 5:837-844. (Pubitemid 24310570)
14. Wolff JA, et al: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
15. Li D, et al: Novel adenoviral gene delivery system targeted against head and neck cancer. Laryngoscope 2008;118: 650-658. (Pubitemid 351496762)
16. Keith WN, et al: Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 2004;1:88-96. (Pubitemid 40823748)
17. Patel MM, et al: Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002;24:1060-1067. (Pubitemid 35379308)
18. Hacein-Bey-Abina S, et al: LMO2- associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419. (Pubitemid 37296260)
19. Kohn DB: Gene therapy for childhood immunological diseases. Bone Marrow Transplant 2008;41:199-205. (Pubitemid 351188918)
20. Barzon L, et al: Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 2003;148:73-80. (Pubitemid 36176007)
21. Chawla SP, et al: Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabineresistant metastatic pancreatic cancer. Mol Ther 2010;18:435-441.
22. Aiuti A, et al: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458.
23. Ott MG, et al: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-409.
24. Brody SL, Crystal RG: Adenovirusmediated in vivo gene transfer. Ann NY Acad Sci 1994;716:90-101; discussion 101-103.
25. OMalley BW Jr, et al: Adenovirusmediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995;55: 1080-1085.
26. Flotte TR: Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007;213:301-305. (Pubitemid 47509706)
27. Raper SE, et al: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-158. (Pubitemid 37272241)
28. Engelhardt JF, et al: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91: 6196-6200. (Pubitemid 24188310)
29. Samulski RJ, Chang LS, Shenk T: Helperfree stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-3828. (Pubitemid 19205454)
30. Varghese S, Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9: 967-978. (Pubitemid 35462560)
31. Chahlavi A, et al: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999;1:162-169.
32. Hu JC, et al: A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clin Cancer Res 2006; 12:6737-6747. (Pubitemid 44876843)
33. Fire A, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811. (Pubitemid 28099681)
34. Behlke MA: Progress towards in vivo use of siRNAs. Mol Ther 2006;13:644-670.
35. Kim DH, Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-184.
36. Morrissey DV, et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007. (Pubitemid 41114035)
37. Higuchi Y, Kawakami S, Hashida M: Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 2010;24: 195-205.
38. Schiffelers RM, et al: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32: e149.
39. Hagstrom JE, et al: A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004;10:386-398. (Pubitemid 39117883)
40. Karagiannis TC, El-Osta A: RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005;12:787-795. (Pubitemid 43086280)
41. Xu F, et al: Phase I and biodistribution study of recombinant adenovirus vectormediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009;16:723-730.
42. Saito K, et al: Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. Laryngoscope 2009;119:665-674.
43. Nemunaitis J, et al: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003;10:341-352. (Pubitemid 36528778)
44. Nemunaitis J, et al: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD genedeleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-6366.
45. Nemunaitis J, et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-298. (Pubitemid 32112839)
46. Khuri FR, et al: a controlled trial of intratumoral ONYX-015, a selectivelyreplicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-885. (Pubitemid 30644745)
47. Xia ZJ, et al: Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004;23:1666-1670.
48. Kurihara Y, et al: Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res 2009;15: 2335-2343.
49. Abuzeid WM, et al: Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 2009;119:1974-1985.
50. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364. (Pubitemid 26272076)
51. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
52. Teknos TN, et al: Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002;24: 1004-1011. (Pubitemid 35217110)
53. Chen SM, et al: Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol Ther 2008;7:734-739.
54. Wang Y, et al: Application of combination of short hairpin RNA segments for silencing VEGF, TERT and Bcl-xl expression in laryngeal squamous carcinoma. Cancer Biol Ther 2008;7:896-901.
55. Futreal PA, et al: A census of human cancer genes. Nat Rev Cancer 2004;4: 177-183. (Pubitemid 38337497)
56. Koch WM, et al: p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-1586. (Pubitemid 26374511)
57. Brachman DG, et al: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52:4832-4836.
58. Huang PI, et al: Targeted genetic and viral therapy for advanced head and neck cancers. Drug Discov Today 2009; 14:570-578.
59. Clayman GL, et al: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
60. Liu TJ, et al: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54:3662-3667.
61. Zhang WW, et al: Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995;6:155-164.
62. Han DM, et al: Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up. Zhonghua Yi Xue Za Zhi 2003; 83:2029-2032.
63. Zhang SW, et al: Recombinant adenovirus- p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma. Zhonghua Zhong Liu Za Zhi 2005;27:426-428.
64. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992;3:75-90.
65. Gleich LL, et al: Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:775-779. (Pubitemid 32619353)
66. McLoughlin JM, et al: TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 2005;12: 825-830. (Pubitemid 41355935)